

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657



VLL\SE\051\2026-27

Date: 30.10.2026

BSE Limited, P J Towers, Dalal Street, Mumbai - 400001. Scrip Code : 524394	National Stock Exchange of India Limited, "Exchange Plaza", Bandra, Kurla Complex, Bandra (E), Mumbai – 400051. Trading Symbol: VIMTALABS
--	--

Dear Sir/Madam,

Sub – Press Release – Unaudited Financial Results – 30th September 2026.

With reference to the subject cited above and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release regarding the announcement of the Unaudited Financial Results for the second quarter and half year ended 30th September 2026.

This is for your information and records.

Thanking you,

For VIMTA LABS LIMITED

SUJANI
VASIREDDI
Digitally signed by
SUJANI VASIREDDI
Date: 2026.10.30
13:54:43 +05'30'



Sujani Vasireddi
Company Secretary & Compliance Officer

Encl: as above.

Vimta Labs Limited Q2 & H1 FY27 Results

Q2 FY27 Total Income at Rs. 1,149 Mn, up 9.9% YoY
EBITDA margins at 35.5%; PAT margin at 17.9%

Hyderabad, October 30, 2026: Vimta Labs Limited (VIMTA) (BSE: 524394, NSE: VIMTALABS), India's leading Contract Research and Testing Organisation, has announced its financial results for the quarter and half year ended September 30, 2026.

Financial Results – Q2 & H1 FY27:

Particulars (₹ Mn)	Q2 FY27	Q1 FY27	QoQ (%)	Q2 FY26	YoY (%)	H1 FY27	H1 FY26	YoY (%)
Total Income	1,149	1,129	1.8%	1045	9.9%	2,278	2,038	11.8%
EBITDA (including other income)	408	411	-0.8%	369	10.5%	819	723	13.2%
EBITDA Margin	35.5%	36.4%		35.3%		36.0%	35.5%	
PAT (continued operations)	206	210	-2.0%	199	3.5%	417	388	7.3%
PAT Margin	17.9%	18.6%		19.1%		18.3%	19.0%	
Basic EPS	4.6	4.7	-2.1%	4.5	3.4%	9.3	8.7	7.0%

Commenting on results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said: "Q2 FY27 marks another quarter of steady, profitable growth for Vimta Labs. Total income rose 9.9% year-on-year to ₹1,149 Mn, while EBITDA grew 10.5%, with margins holding firm at 35.5%. For the first half, total income grew 11.8% and EBITDA 13.2%, reflecting the strength and consistency of our business. Our pharmaceutical and food research and testing services continue to anchor this growth, and the start of revenue from our biologics CRAD services is a significant milestone that broadens our scientific capabilities. As we enter the second half of the year, we are well positioned to build on this strong base, supported by a favourable industry environment, expanded infrastructure and a diversified portfolio of research and testing services. We are confident in Vimta's ability to deliver sustained growth and create long-term value for all our stakeholders."

Key Result Highlights for the Q2 & H1 FY27:

Q2 FY27

- ✓ Total Income for Q2 FY27 was at ₹1,149 Mn
- ✓ EBITDA for Q2 FY27 was ₹408 Mn; EBITDA margin was at 35.5%
- ✓ PBT for Q2 FY27 was at ₹275 Mn
- ✓ Q2 FY27 PAT was at ₹206 Mn; PAT margin was at 17.9%
- ✓ Basic EPS in Q2 FY27 was ₹4.6

H1 FY27

- ✓ Total Income for H1 FY27 was at Rs. 2,278 Mn
- ✓ EBITDA for H1 FY27 was Rs. 819 Mn; EBITDA margin was at 36.0%
- ✓ PBT for H1 FY27 was at Rs. 559 Mn
- ✓ H1 FY27 PAT was at Rs. 417 Mn; PAT margin was at 18.3%
- ✓ Basic EPS in H1 FY27 was Rs. 9.3

ABOUT VIMTA LABS LIMITED:

Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides environmental assessments and testing services.

CAUTIONARY STATEMENT:

This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at Vimta Labs Siva Kambhampati (Chief Financial Officer) Siva.Kambhampati@Vimta.com Ernst & Young Siddesh Chawan Siddesh.Chawan@in.ey.com Advait Bhadekar Advait.bhadekar@in.ey.com	Registered Office Plot Number 142, IDA Phase 2, Cherlapally, Hyderabad Telangana, India. 500051 CIN: L24110TG1990PLC011977 ISIN: INE579C01029 NSE Code: VIMTALABS BSE CODE: 524394 Website: www.vimta.com
---	--